



TBI Endpoints Development (TED)

Consensus Conference 1

Agenda | February 2-3, 2015

Natcher Conference Center | NIH Campus

DAY 1 | February 2, 2015

I. Breakfast,
Introductions
& Overview
7:45-9:15am

Continental Breakfast at NIH Natcher Center (7:45 - 8:30am)
Geoff Manley, MD PhD | Introductions and Overview of the TED Technical Objectives and Aims (**8:30am**)
Col. Dallas Hack | “The TED Initiative’s Mission and Vision”
Q&A

II. Moderated
Tri-Part Panel
Sessions
9:15am-
12:15pm

Segment I Panel | FDA Regulatory Pathways

Co-Moderators | **Diane Stephenson, PhD** C-Path and **Nicholas Kozauer, MD** Quintiles
Rapporteurs | **Raquel Gardner, MD** and **Brian Fabian, MPA**

Lead Speaker | **Douglas Throckmorton, MD** (Center for Drug Evaluation & Research [CDER] Deputy Center Director for Regulatory Programs) “Overview of FDA Innovation”

Panelists | “FDA Divisions’ Roles in the Regulatory Readiness and DDT/MDDT Qualification Processes”

Billy Dunn, MD (Director, Division of Neurology Products, [CEDR])

Peter Como, PhD (Lead Reviewer and Neuropsychologist: Division of Neurological and Physical Medicine Devices, Neurodiagnostic and Neurosurgical Devices Branch)

Allison Kumar (Sr. Project Manager: Office of the Center Director - Center for Devices and Radiological Health [CDRH])

Yasmin Choudhry, MD (Medical Officer and Reviewer: Study Endpoints and Labeling Development [SEALD] Office of New Drugs (OND) [CDER])

Christopher Leptak, MD (OND Biomarker Diagnostic Lead and Scientific Lead: Letter of Support) [CDER])

James Kaiser, MD (Medical Officer and Scientific Lead: CDER Critical Path Innovation Meeting [CPIM])

Q&A | **BREAK – 15 minutes**

Segment II Panel | Industry Perspectives on Regulatory Processes

Moderator | **Jam Ghajar, MD PhD** Director, Stanford Concussion and Brain Performance Center

Panelists

Jonathan Murray and team (Victor Miranda, Pam Schaub, Glen Sabin) | GE

Beth McQuiston, MD RD | Abbott Diagnostics

Donna Edmonds | ImmunArray

Dick Moberg | Moberg Research

Mark Lovell, PhD | ImPACT

Q&A | **BREAK – 10 minutes**

Segment III Panel | Regulatory Readiness Case Studies

Moderator | **Ramona Hicks, PhD** One Mind

Panelists | **Diane Stephenson, PhD** C-Path; **Michael Ropacki, PhD** Janssen; **Michael Singer, PhD** BrainScope

Q&A

III. Lunch
12:15-1pm

Box lunches | Self-selected seating in the Atrium and breakout rooms


TBI Endpoints Development (TED)

Consensus Conference 1

Agenda | February 2-3, 2015

Natcher Conference Center | NIH Campus

DAY 1 February 2, 2015	
<p>IV. Full Conference, followed by EWG Breakouts 1pm-4:30pm</p>	<p>Geoff Manley, MD, PhD Introduction and charge to Expert Working Groups, Data Aggregation and Integration, and Landscape Analyses</p> <p>Expert Working Group (EWG) Breakouts</p> <ol style="list-style-type: none"> 1) Landscape Analyses; Identify existing COAs and biomarkers to be analyzed 2) Define roles of EWGs' membership 3) Create workstreams to achieve TED Stage I Aims <p>OUTCOMES EWG Lead Michael McCrea, PhD Co-Leads Murray Stein, MD; Harvey Levin, PhD; Joseph Giacino, PhD; John Whyte, MD PhD Rapporteurs Yelena Guller Bodien, PhD and Sabrina Rose Taylor, PhD</p> <p>BLOOD-BASED BIOMARKER EWG Lead Ramon Diaz-Arrastia, MD PhD Co-Lead Kevin Wang, PhD Rapporteur John Yue, BS</p> <p>NEUROIMAGING BIOMARKER EWG Lead Pratik Mukherjee, MD PhD Co-Lead Arthur Toga, PhD Rapporteur Christine Mac Donald, PhD</p> <p>EMERGING TECHNOLOGIES EWG Lead Jam Ghajar, MD PhD Co-Lead Mona Hicks, PhD Rapporteur Ethan Winkler, MD PhD</p>
<p>V. Day 1 Close 4:45-5:00pm</p>	<p>Geoff Manley Preparation for Day 2</p>



TBI Endpoints Development (TED)

Consensus Conference 1

Agenda | February 2-3, 2015

DAY 2 | February 3, 2015

<p>VI. Breakfast and Welcome 7:45-8:45am</p>	<p>Continental Breakfast at NIH Natcher Center (7:45am-8:30am) Geoff Manley Welcome 8:30am</p>
<p>VII. EWG Reports 8:45-11:00am</p>	<p>EWG Leads Report-back from EWG breakout sessions BREAK 15 mins</p>
<p>VIII. Forward Planning/Adjourn 11:15am-1:00pm</p>	<p>Geoff Manley and EWG Leads Forward plan Execution of remaining Stage I Technical Objectives and Aims Q&A Wrap-up and Forward Plan</p>